Multiple sclerosis and related disorders · 2025
Post marketing real-world experience of ravulizumab in NMOSD.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jacob Anu, Mahmoud Azza, Saab Rami R, Deif Ali A, Lee Gina, Elhabet Suzi, Eldweik Luai, Mifsud Victoria, Benedetti Beatrice, Shatila Ahmed
Аннотация
BACKGROUND: Ravulizumab is a long-acting complement C5 inhibitor recently approved for treatment of AQP4-IgG-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD). No post-marketing real-world data is currently available.
OBJECTIVE: To assess whether the real-world clinical experience of ravulizumab in AQP4-NMOSD is similar to that seen in pivotal clinical trials.
DESIGN: A multicenter retrospective cohort study that uses standardized data extracted from medical records.
METHODS: We conducted a multi-center retrospective cohort study of AQP4-NMOSD patients treated with ravulizumab at two major neurological centers in the UAE. Data on demographics, disease characteristics, relapse rates, EDSS scores, and treatment-related adverse events were extracted from electronic medical records. Annualized relapse rates and EDSS changes were calculated, and adverse events were summarized using counts and frequencies.
RESULTS: Nine AQP4-NMOSD patients (female:male ratio 8:1) were treated with ravulizumab. Median disease duration was 6.6 years (IQR 6.5), and 44.4% were treatment-naïve. Over a median follow-up of 14.5 months (IQR 6.25), all patients remained relapse-free, with annualized relapse rate decreasing from 0.9 ± 0.5 to 0 (p = 0.0012). Mean EDSS improved from 3.9 ± 2.4 pre-treatment to 2.2 ± 3 post-treatment (p = 0.02). Two patients (22.2%) experienced mild infusion reactions, and two patients (22.2%) developed uncomplicated infections. No cases of meningitis were observed. One patient discontinued therapy due to insurance denial.
CONCLUSION: Early post-marketing real-world experience with ravulizumab in the UAE is consistent with pivotal trial results and aligns with the safety and efficacy profiles reported for other complement-targeted therapies; however, findings are limited by the small sample size and short follow-up.
OBJECTIVE: To assess whether the real-world clinical experience of ravulizumab in AQP4-NMOSD is similar to that seen in pivotal clinical trials.
DESIGN: A multicenter retrospective cohort study that uses standardized data extracted from medical records.
METHODS: We conducted a multi-center retrospective cohort study of AQP4-NMOSD patients treated with ravulizumab at two major neurological centers in the UAE. Data on demographics, disease characteristics, relapse rates, EDSS scores, and treatment-related adverse events were extracted from electronic medical records. Annualized relapse rates and EDSS changes were calculated, and adverse events were summarized using counts and frequencies.
RESULTS: Nine AQP4-NMOSD patients (female:male ratio 8:1) were treated with ravulizumab. Median disease duration was 6.6 years (IQR 6.5), and 44.4% were treatment-naïve. Over a median follow-up of 14.5 months (IQR 6.25), all patients remained relapse-free, with annualized relapse rate decreasing from 0.9 ± 0.5 to 0 (p = 0.0012). Mean EDSS improved from 3.9 ± 2.4 pre-treatment to 2.2 ± 3 post-treatment (p = 0.02). Two patients (22.2%) experienced mild infusion reactions, and two patients (22.2%) developed uncomplicated infections. No cases of meningitis were observed. One patient discontinued therapy due to insurance denial.
CONCLUSION: Early post-marketing real-world experience with ravulizumab in the UAE is consistent with pivotal trial results and aligns with the safety and efficacy profiles reported for other complement-targeted therapies; however, findings are limited by the small sample size and short follow-up.